Atsushi Miyanohara

Title: Atsushi Miyanohara: Innovator in Neuropathic Pain Treatment

Introduction

Atsushi Miyanohara is a prominent inventor based in La Jolla, California. He has made significant contributions to the field of neuropathic pain treatment, holding a total of 5 patents. His innovative approaches have the potential to transform therapeutic practices in this area.

Latest Patents

Miyanohara's latest patents include a method and composition for treating neuropathic pain. This invention provides a therapy through subpial administration of small quantities of a composition aimed at spinal segment-specific upregulation of GAD65 (glutamate decarboxylase) gene and VGAT (vesicular GABA transporter) gene. This method is effective for inducing nociceptive effects by enhancing the release of vesicular GABA from infected dorsal horn neurons into the synaptic cleft. Another notable patent is the spinal subpial gene delivery system, which encompasses delivery devices, systems, and methods for spinal delivery of cells, drugs, or vectors. This system enables subpial delivery, resulting in nearly complete spinal parenchymal AAV9-mediated gene expression or distribution in both white and grey matter.

Career Highlights

Throughout his career, Miyanohara has worked with esteemed institutions such as the University of California and City of Hope. His work has been instrumental in advancing the understanding and treatment of neuropathic pain.

Collaborations

Miyanohara has collaborated with notable colleagues, including Theodore Friedmann and Martin Marsala. Their combined expertise has contributed to the development of innovative solutions in the field.

Conclusion

Atsushi Miyanohara's contributions to neuropathic pain treatment through his patents and collaborations highlight his role as a leading inventor in the medical field. His work continues to pave the way for advancements in therapeutic techniques.